Bitter Diterpenoids

Compound Class	Clerodane-type furanoid diterpenoids and diterpenoid lactones; the bitter principles of guduchi
Representative Members	Columbin, tinosporide, tinosporaside, furanolactone diterpenes; co-occurring with alkaloids and polysaccharides
Botanical Sources	Tinospora cordifolia (guduchi; giloy; amrita)
Plant Part(s)	Stem
Typical Standardisation	Bitter diterpenoids by HPLC; 2.5% common commercial grade
Primary Applications	Immunomodulatory and adaptogenic formulation; traditional Ayurvedic rasayana positioning
Claim Strength (Overview)	Emerging — immunomodulatory activity is preclinically well documented; a significant hepatotoxicity signal emerged in 2021–22 and must be surfaced
Buy from Herbuno	Bitter Diterpenoids 2.5% Powder (Guduchi Extract) | Standardized Tinospora cordifolia → Guduchi (Giloy) Extract Powder →

Name origin: "Bitter diterpenoids" is a functional standardization term rather than a strict chemical class name, denoting the clerodane-type furanoid diterpenes and diterpenoid lactones responsible for guduchi’s intense bitterness. The plant’s Sanskrit name amrita — nectar of immortality — signals the extraordinarily high standing it holds in Ayurveda; guduchi is its classical name and giloy the common Hindi one. Traditional use: Tinospora cordifolia is a cornerstone Ayurvedic rasayana, employed for centuries as an immunomodulator, adaptogen, and general rejuvenative, and prescribed for fever (it is a classical jvara remedy), jaundice, diabetes, and inflammatory conditions. Its climbing stems are the medicinal part, and a starchy preparation called guduchi satwa is a traditional derivative. Safety context: This monograph must address a serious and recent development directly. During the COVID-19 pandemic, giloy was heavily promoted across India as an "immune booster," consumption rose sharply, and a substantial cluster of herb-induced liver injury cases followed — documented in a multicentre national study and subsequent case series. The signal is real, has been contested by some Ayurvedic clinicians on methodological grounds, and is presented here with both sides stated. A page on this compound that omitted it would be indefensible. Commercial source: Tinospora cordifolia stem extract standardized to bitter diterpenoid content is the commercial format; polysaccharide-standardized guduchi extract is a separate and chemically distinct grade.

---

Evidence for Bitter Diterpenoids Applications

The hepatotoxicity signal must be stated before any efficacy discussion. A large retrospective Indian multicentre study spanning 13 centres at nine locations, conducted after giloy was heavily promoted as a COVID-19 immune booster, reported 43 patients with liver injury temporally associated with giloy use, with a median time from initial consumption to symptom onset of 46 days. Patients presented with acute hepatitis, acute worsening of chronic liver disease, or acute liver failure; causality assessment indicated probable liver injury in 67.4%; and the authors concluded that giloy is associated with acute hepatitis with autoimmune features and can unmask autoimmune hepatitis in people with silent autoimmune-related chronic liver disease (Kulkarni 2022 Hepatol Commun). Acute liver failure is among the reported presentations. Claim strength: Moderate (adverse signal; contested methodology).

Intellectual honesty requires noting that this finding has been formally contested. A published response argued that the study generalized about the safety of a widely used herb on the basis of a single, insufficiently designed retrospective study, criticizing it for enrolling patients with liver injury and a history of giloy use without reporting the total number screened or the reasons for exclusion. This is a legitimate methodological critique of a retrospective design, and it is fair to say the signal is an association drawn from case ascertainment rather than a controlled demonstration of causation. It is not, however, a refutation, and multiple independent case series report the same pattern. Claim strength: Emerging (contested).

A plausible mechanistic account connects the toxicity to the very property the herb is marketed for, which is worth pausing on. Guduchi is genuinely immunostimulatory — and the reported injury pattern is autoimmune-like hepatitis, with anti-nuclear antibody the most commonly detected autoantibody and liver biopsy showing autoimmune features. If immune stimulation is the mechanism, then the hepatotoxicity is not an impurity problem or an adulteration problem to be engineered away, but an on-target consequence of the herb’s intended pharmacology in susceptible individuals. That is a materially different risk profile from a contaminant issue. Claim strength: Emerging.

Turning to the efficacy side, the immunomodulatory activity is genuinely well documented preclinically. Tinospora cordifolia exhibits immunomodulatory, antioxidant, anti-inflammatory, and antiviral activities attributed to a rich array of bioactive compounds including alkaloids, diterpenoid lactones, and polysaccharides (Review 2025). Cellular work has demonstrated that guduchi treatment enhances macrophage phagocytosis and pinocytosis in vitro, with increased phagocytosis of both non-infective and live infective microorganisms. The activity is real; the question is whether it is desirable in a given individual. Claim strength: Emerging.

A critical standardization point that the toxicity discussion makes urgent rather than academic: guduchi’s activity is distributed across at least three chemically unrelated constituent groups — the bitter diterpenoids documented on this page, the alkaloids, and the polysaccharides (including a characterized 25 kDa immunomodulatory protein found in the stem but notably absent from the leaf and from several commercial preparations). A "bitter diterpenoids 2.5%" specification therefore captures one fraction of a multi-component herb, and it remains unestablished which fraction carries the hepatotoxic liability. Formulators cannot currently assume that standardizing on diterpenoids selects away from the risk. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries Tinospora cordifolia stem extract standardized to 2.5% bitter diterpenoids, alongside a separately standardized polysaccharide grade (40%), unstandardized guduchi extract powder, organic whole-stem powder, dehydrated stems, and water-soluble and oil-soluble extracts. Buyers should note that the diterpenoid and polysaccharide grades are chemically distinct fractions with different activity profiles, and that it is not currently established which fraction carries the hepatotoxic liability.

Given the liver-injury signal, presenting a confident dosing recommendation for this ingredient would be inappropriate. The multicentre study reported a median 46 days from initial consumption to symptom onset, indicating that injury emerges over weeks of sustained use rather than acutely — which argues against open-ended long-term supplementation and in favour of defined, time-limited courses if the ingredient is used at all. Traditional Ayurvedic use employs guduchi at gram-scale doses of stem powder; formulators should not translate that precedent into a safety assurance for concentrated modern extracts, since the promotional surge that preceded the case cluster involved exactly such concentrated products.

Analytical verification should specify bitter diterpenoid content by HPLC. Two further points are material. First, botanical authentication is unusually important here: Tinospora cordifolia is commonly adulterated with or substituted by Tinospora sinensis and by T. cordifolia grown on neem (Azadirachta indica), which have differing phytochemistry, and species misidentification has been raised as a possible contributor to the toxicity reports. Second, chemical and toxicological analysis of retrieved giloy samples formed part of the multicentre investigation, underscoring that material provenance and authentication are central rather than peripheral concerns for this ingredient.

Any product containing Tinospora cordifolia should carry clear liver-injury caution language. The documented picture is: herb-induced liver injury with autoimmune features, capable of unmasking silent autoimmune hepatitis; presentations including acute hepatitis, acute-on-chronic liver failure, and acute liver failure; median onset around 46 days of use. Individuals with any pre-existing liver disease, and particularly with known or suspected autoimmune conditions, should be advised against use. Users should be told to discontinue and seek medical attention on any sign of jaundice, dark urine, or unexplained fatigue. Because the injury may be an on-target consequence of immune stimulation, caution is also warranted for anyone on immunosuppressive therapy or with an autoimmune diagnosis.

---

Frequently Asked Questions — Bitter Diterpenoids

Is giloy associated with liver injury?
Yes. A multicentre Indian study across 13 centres reported 43 patients with liver injury temporally associated with giloy use following its heavy promotion as a COVID-19 immune booster, with median onset around 46 days. Presentations included acute hepatitis, acute-on-chronic liver failure, and acute liver failure, with probable causality in 67.4%. The finding has been contested methodologically but multiple independent case series report the same pattern.

Why might an immune-boosting herb damage the liver?
The reported injury pattern is autoimmune-like hepatitis, with anti-nuclear antibody the most common autoantibody detected. If immune stimulation is the mechanism, the hepatotoxicity would be an on-target consequence of the herb's intended pharmacology in susceptible individuals — not a contaminant problem that could be engineered away. That is a materially different risk profile.

Does standardizing on bitter diterpenoids avoid the risk?
This is not currently established. Guduchi's activity is distributed across at least three unrelated constituent groups — bitter diterpenoids, alkaloids, and polysaccharides including a 25 kDa immunomodulatory protein. Which fraction carries the hepatotoxic liability remains unknown, so formulators cannot assume that standardizing on diterpenoids selects away from the risk.

Is the immunomodulatory evidence for guduchi real?
The preclinical evidence is genuine: cellular work shows guduchi enhances macrophage phagocytosis and pinocytosis, and reviews document immunomodulatory, antioxidant, anti-inflammatory, and antiviral activity across its alkaloids, diterpenoid lactones, and polysaccharides. The activity is real; the open question is whether that activity is desirable in a given individual given the autoimmune-hepatitis signal.

Related compounds: Berberine, Andrographolide, Withanolides, Beta-Glucans

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery